02654nas a2200205 4500000000100000008004100001260004400042653002400086653001700110653002300127100001100150700001400161700002100175700001600196245010200212856009100314490000700405520202200412022001402434 2022 d bSpringer Science and Business Media LLC10aInfectious Diseases10aParasitology10apraziquantel (PZQ)1 aKura K1 aAyabina D1 aHollingsworth TD1 aAnderson RM00aDetermining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni uhttps://parasitesandvectors.biomedcentral.com/track/pdf/10.1186/s13071-022-05178-x.pdf0 v153 a

Background

In January 2021, the World Health Organization published the 2021–2030 roadmap for the control of neglected tropical diseases (NTDs). The goal for schistosomiasis is to achieve elimination as a public health problem (EPHP) and elimination of transmission (EOT) in 78 and 25 countries (by 2030), respectively. Mass drug administration (MDA) of praziquantel continues to be the main strategy for control and elimination. However, as there is limited availability of praziquantel, it is important to determine what volume of treatments are required, who should be targeted and how frequently treatment must be administered to eliminate either transmission or morbidity caused by infection in different endemic settings with varied transmission intensities.

Methods and Results

In this paper, we employ two individual-based stochastic models of schistosomiasis transmission developed independently by the Imperial College London (ICL) and University of Oxford (SCHISTOX) to determine the optimal treatment strategies to achieve EOT. We find that treating school-age children (SAC) only is not sufficient to achieve EOT within a feasible time frame, regardless of the transmission setting and observed age–intensity of infection profile. Both models show that community-wide treatment is necessary to interrupt transmission in all endemic settings with low, medium and high pristine transmission intensities.

Conclusions The required MDA coverage level to achieve either transmission or morbidity elimination depends on the prevalence prior to the start of treatment and the burden of infection in adults. The higher the worm burden in adults, the higher the coverage levels required for this age category through community-wide treatment programmes. Therefore, it is important that intensity and prevalence data are collected in each age category, particularly from SAC and adults, so that the correct coverage level can be calculated and administered.

 a1756-3305